Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Ilaris. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Canakinumab (sold as Ilaris), first approved Jun 17, 2009, with 7 new uses approved and 0 published complete response letters.
First approved in Japan 27 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
IlarisA drug with a new indication and a new dosage for the treatment of Schnitzler syndrome. · Novartis Pharma K.K. · Feb 19, 2026
IlarisA drug with a new indication and a new dosage for the treatment of adult-onset Still's disease in patients who have not responded sufficiently to… · Novartis Pharma K.K. · Mar 27, 2025
IlarisDrugs with a new additional indication and a new dosage for the treatment of systemic juvenile idiopathic arthritis in patients who have not responded… · Novartis Pharma K.K. · Jul 2, 2018
IlarisA drug with new additional indications and a new dosage for the treatment of patients with familial Mediterranean fever who have not responded sufficiently… · Novartis Pharma K.K. · Dec 19, 2016 · Review report
Ilaris, new ingredientA drug with a new active ingredient indicated for the treatment of cryopyrin-associated periodic syndrome. · Novartis Pharma K.K. · Sep 26, 2011
Clinical Trials
15 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
